CDEK
← All drugs Report issue

milrinone

Trade name: primacor

Small moleculeapproved

Approved

Dec 31, 1987

Milrinone, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. Milrinone inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, Milrinone also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. Milrinone is indicated for the treatment of congestive heart failure. Milrinone was marketed under the brand name Primacor. — NCATS

Clinical trial activity

47 trials · 71 clinical orgs · 20 marketing orgs

Phase 1
9
Phase 2
27
Phase 3
6
Phase 4
7

Earliest trial started Jan 1, 2003 (NCT01621971)

Timeline

1980s

  1. Dec 31, 1987

    Sanofi-Aventis — Earliest FDA Approval

  2. Dec 31, 1987

    Sanofi-Aventis — NDA Secondary Org

  3. Dec 31, 1987

    Sanofi-Aventis — NDA Organization

2000s

  1. May 28, 2002

    Hospira — Marketing Organization

  2. May 28, 2002

    West-Ward Pharmaceutical — Marketing Organization

  3. May 28, 2002

    Fresenius — Marketing Organization

  4. May 28, 2002

    Baxalta — Marketing Organization

  5. May 28, 2002

    Baxter — Marketing Organization

  6. Aug 2, 2002

    International medicated systems ltd. — Marketing Organization

  7. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

  8. Jun 16, 2003

    Mylan — Marketing Organization

  9. Aug 18, 2004

    B. Braun — Marketing Organization

  10. Jul 20, 2005

    Renaissance Pharma — Marketing Organization

  11. Jul 20, 2005

    Woodward — Marketing Organization

  12. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

  13. Oct 31, 2006

    Gland Pharma Ltd — Marketing Organization

  14. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 21, 2010

    Hikma — Marketing Organization

2020s

  1. Mar 24, 2020

    Nanjing King-Friend — Marketing Organization

  2. Mar 24, 2020

    Meitheal — Marketing Organization

  3. Jul 16, 2020

    Fosun — Marketing Organization

  4. Sep 3, 2020

    Aurobindo Pharma — Marketing Organization

  5. Sep 3, 2020

    Eugia Pharma — Marketing Organization

  6. Apr 16, 2021

    Caplin Point Laboratories — Marketing Organization

  7. Jan 23, 2023

    Shandong Lanjin Pharmaceuticals Co.,Ltd — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedDec 31, 1987

Chemistry & pharmacology

Loading structure…

SMILES

Cc1[nH]c(=O)c(C#N)cc1-c1ccncc1
Mol. weight
211.22 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • 1,6-dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile
  • 1,6-dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile
  • corotrop
  • corotrope
  • milrinona
  • milrinona
  • milrinone
  • milrinone
  • milrinone
  • milrinone
  • milrinone
  • milrinone
  • milrinone
  • milrinone
  • milrinone lactate
  • milrinone lactate
  • milrinone lactate
  • milrinone lactate
  • milrinonum
  • milrinonum
  • primacor
  • primacor
  • primacor
  • primacor
  • primacor
  • primacor
  • primacor
  • win-472032
  • win-472032
  • win-47203-2
  • win-47203-2

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07144267N/AOct 1, 2025Mansoura University
NCT06679855Phase 3Feb 1, 2025National Heart, Lung, and Blood Institute (NHLBI), National Institute of Child Health and Human Development (NICHD)
NCT06562036N/ADec 1, 2023ICH Multan, Pakistan, RESnTEC, Institute of Research
NCT05700617Early Phase 1 (Phase 1)Jul 31, 2023University of Chicago
NCT05838846Phase 2/Phase 3 (Phase 3)Apr 1, 2023Ain Shams University, Menoufia University
NCT05450328Phase 2Sep 1, 2022University of Montreal
NCT05267886Phase 4Mar 5, 2022University of Ottawa
NCT05122884Phase 2Dec 1, 2021Mahidol University
NCT05132153Phase 4Oct 17, 2021Ain Shams University
NCT04718350N/AJan 27, 2021Aretaieion University
NCT04484675Phase 4Jul 20, 2020Zagazig University
NCT05131867Phase 2Jul 1, 2020Zagazig University
NCT04369573Phase 4May 4, 2020University of Milan
NCT04362527Phase 3Apr 30, 2020APHP - Hôpital Necker, Central Hospital, Dijon, France, University Clermont Auvergne, University Hospital, Tours, University of Angers, University of Montpellier, University of Nantes, University of Poitiers, University of Rennes, University of Strasbourg, University of Western Brittany
NCT04282629Phase 2Mar 31, 2020University of Toulouse
NCT03855579Phase 4Mar 6, 2019Assiut University
NCT03823781Phase 3Feb 28, 2019Jiao Tong University, Shanghai Children Medicine Center
NCT03217331Phase 1/Phase 2 (Phase 2)Mar 6, 2018Cardiora Pty. Ltd.
NCT03207165Phase 4Aug 30, 2017University of Ottawa
NCT02951130Phase 2Jun 1, 2017National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), State University of New York, Buffalo
Showing 20 of 47 trials
Page 1 / 3

Organizations

Research & Development (71)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of GothenburgAcademic/Hospital4432014
Ain Shams UniversityAcademic/Hospital3132015
University of MontrealAcademic/Hospital3312006
Assiut UniversityAcademic/Hospital2222015
Monash UniversityAcademic/Hospital2212013
National Institute of Child Health and Human Development (NICHD)Government2222017
The Alfred HospitalAcademic/Hospital2012013
University of OttawaAcademic/Hospital2212017
Vanderbilt UniversityAcademic/Hospital2222017
Zagazig UniversityAcademic/Hospital2222020
American Heart AssociationAcademic/Hospital1012007
American Medical AssociationAcademic/Hospital1012010
APHP - Hôpital NeckerAcademic/Hospital1012020
Aretaieion UniversityAcademic/Hospital1112021
Arizona State UniversityAcademic/Hospital1112015
Bedford PharmaceuticalsFor profit1012010
Canadian Anesthesiologists' SocietyAcademic/Hospital1012009
Canadian Institutes of Health Research (CIHR)Academic/Hospital1012006
Cardiora Pty. Ltd.For profit1112018
Central Hospital, Dijon, FranceAcademic/Hospital1012020
71 organizations
Page 1 / 4

Marketing (26)

OrganizationOrg typeRelationshipDate
Aurobindo PharmaFor profitMKTGSep 3, 2020
B. BraunFor profitMKTGAug 18, 2004
BaxaltaFor profitSYNSep 21, 2004
BaxaltaFor profitMKTGMay 28, 2002
BaxterFor profitMKTGMay 28, 2002
Caplin Point LaboratoriesFor profitMKTGApr 16, 2021
Eugia PharmaFor profitMKTGSep 3, 2020
FosunFor profitMKTGJul 16, 2020
FreseniusFor profitMKTGMay 28, 2002
Gland Pharma LtdFor profitMKTGOct 31, 2006
Gland Pharma LtdFor profitSYNJul 16, 2020
HikmaFor profitMKTGJan 21, 2010
HikmaFor profitSYNMay 28, 2002
HikmaFor profitSYNMay 28, 2002
HospiraFor profitMKTGMay 28, 2002
HospiraFor profitSYNSep 3, 2014
International medicated systems ltd.For profitMKTGAug 2, 2002
MeithealFor profitMKTGMar 24, 2020
MylanFor profitMKTGJun 16, 2003
Nanjing King-FriendFor profitMKTGMar 24, 2020
Renaissance PharmaFor profitMKTGJul 20, 2005
Sanofi-AventisFor profitNDA2Dec 31, 1987
Sanofi-AventisFor profitNDADec 31, 1987
Shandong Lanjin Pharmaceuticals Co.,LtdFor profitMKTGJan 23, 2023
West-Ward PharmaceuticalFor profitMKTGMay 28, 2002
WoodwardFor profitMKTGJul 20, 2005